Anika Therapeutics, Inc. Revenue from Contract with Customer, Including Assessed Tax
Anika Therapeutics, Inc. (ANIK) reported Revenue from Contract with Customer, Including Assessed Tax of $26.79 million for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-10-26.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2018-10-26
- Anika Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2018-09-30 was $26.79M, a 1.46% decline year-over-year.
- Anika Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2018-06-30 was $30.55M, a 8.71% decline year-over-year.
- Anika Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2018-03-31 was $21.26M, a 9.07% decline year-over-year.
- Anika Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2017-09-30 was $27.18M.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month |
|---|---|---|---|
| 2018-09-30 | $26.79M 10-Q · filed 2018-10-26 | $57.34M derived: sum of 2 quarters · filed 2018-10-26 | $78.60M 10-Q · filed 2018-10-26 |
| 2018-06-30 | $30.55M 10-Q · filed 2018-07-31 | $51.81M 10-Q · filed 2018-07-31 | |
| 2018-03-31 | $21.26M 10-Q · filed 2018-05-10 | ||
| 2017-09-30 | $27.18M 10-Q · filed 2018-10-26 | $60.65M derived: sum of 2 quarters · filed 2018-10-26 | $84.03M 10-Q · filed 2018-10-26 |
| 2017-06-30 | $33.46M 10-Q · filed 2018-07-31 | $56.85M 10-Q · filed 2018-07-31 | |
| 2017-03-31 | $23.39M 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |